STOPFLUID: Impact of an Echographic Algorithm on Hemodynamic Optimization in the First 4 Days of Septic Shock Management

Sponsor
Centre Hospitalier Universitaire de Nīmes (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06043505
Collaborator
(none)
136
1
2
13
10.5

Study Details

Study Description

Brief Summary

Fluid management is one of the key issues in the initial management of septic shock (SS). Fluid overload and hypovolemia have been associated with increased mortality in several trials. Transthoracic echocardiography (TTE) and lung ultrasound are recommended for haemodynamic assessment in critically ill patients. However, the benefit of hemodynamic optimisation using echography has not been yet evaluated. The purpose of this multicenter, controlled, randomized trial is to assess the impact of an echocardiographic algorithm of hemodynamic optimization on fluid management in septic patients during the first 4 days of therapy.

Condition or Disease Intervention/Treatment Phase
  • Other: Echographic hemodynamic algorithm guiding fluid resuscitation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
136 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Impact of an Echographic Algorithm on Hemodynamic Optimization in the First 4 Days of Septic Shock Management: a Multicentric, Randomized, Controlled, Open Label Pilot-study
Anticipated Study Start Date :
Sep 26, 2023
Anticipated Primary Completion Date :
Sep 26, 2024
Anticipated Study Completion Date :
Oct 26, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional Strategy: STOPFLUID Algorithm

Fluid management is optimised using the specific echographic hemodynamic algorithm ('STOPFLUID') of this study described during the first 4 days of septic shock. Fluid bolus will not be administered in case of increased left ventricle filling pressures; fluid challenge will be performed based on dynamic indices and fluid depletion will be considered on the basis of Lung UltraSound (LUS) assessment.

Other: Echographic hemodynamic algorithm guiding fluid resuscitation
Ultrasound Hemodynamic Algorithm (UHA): st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3) E/Ea >14 and/or E/A >2 YES => No filling test => Bilateral anterior B lines on lung ultrasound => YES => Consider administration of diuretics NO => Step 2 nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase >15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test YES => consider 250ml bolus filling NO => stop vascular filling rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B YES => depletion NO => stop vascular filling

No Intervention: Standard Strategy

Fluid management will be handled according to standard care, without using transthoracic echocardiography (TTE) during the first 4 days of septic shock management. Haemodynamic monitoring including pulmonary artery catheter, transpulmonary thermodilution, or any other device will be left at the physician's discretion. TTE will be allowed in the standard group only for excluding cardiac tamponade in case of clinical suspicion (one or more of the following signs: jugular distension, pulsus paradoxus)

Outcome Measures

Primary Outcome Measures

  1. Volume of vascular filling during the first 4 days [Day 4]

    This takes into account the cumulative volume of vascular filling administered to improve cardiac output during the 4 first days, measured in Liter (L)

Secondary Outcome Measures

  1. .Analysis of the primary endpoint related to ARDS ([acute respiratory distress syndrome, according to Berlin criteria) [Day 4]

    Analysis of the primary endpoint in relation with presence or absence of ARDS at inclusion

  2. Analysis of the primary endpoint related to severe renal dysfunction [Day 4]

    Analysis of the primary endpoint in relation with severe renal dysfunction defined as a KDIGO (Kidney Disease Improving Global Outcomes) score ≥3 vs <3.

  3. Analysis of the primary endpoint in relation with patient severity [Day 4]

    Analysis of the primary endpoint in relation withpatient severity according to SAPS 2 (Simplified Acute Physiology Score) score: <15, 15-30, >30

  4. Mortality [Day 28]

    Patient deceased: yes or no

  5. Number of days alive without failure at Day 28 [Day 28]

    Number of days without failure

  6. Time to normalization of lactatemia (<2 mmol/l) [Day 4]

    Represents time from randomization to first lactatemia <2 mmol/l in hours

  7. Fluid balance in L [Day 4]

    The fluid balance will be deduced from the daily weight changes in kilograms, the density of water being equal to 1

  8. Therapeutic adjustments including bolus vascular filling, changes in vasopressor flow, and administration of diuretics [Day 4]

    Number of therapeutic adjustments

  9. Length of stay in ICU (ready for discharge) [Day 28]

    Length of stay in ICU from randomization to discharge in days

  10. Length of stay in hospital [Day 28]

    Number

  11. Adverse effects [Day 28]

    Number and type of adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

All eligible patients will have a cardiac echocardiogram prior to inclusion for the sole purpose of eliminating special situations that are part of the non-inclusion criteria listed below.

Inclusion Criteria

  • Patient in an intensive care unit who develops septic shock on admission or during hospitalization, as defined by SEPSIS-3 criteria.

  • Patient or trusted person / legal representative / family member / curator / guardian who has given free and informed consent and has signed the consent form or patient included in an emergency situation.

  • Patient affiliated or beneficiary of a health insurance plan.

  • Patient at least (≥) 18 years of age.

Exclusion Criteria:
  • Refusal of consent.

  • Patient under court protection or guardianship.

  • Moribund patient with a life expectancy of less than 48 hours.

  • Non-echogenic patient.

  • Cardiac tamponade.

  • Infective endocarditis.

  • Intracavitary thrombus.

  • Dilated cardiomyopathy with LVEF (Left Ventricular Ejection Fraction<40%.

  • Parturient or nursing patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Nimes Nîmes France 30029

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nīmes

Investigators

  • Principal Investigator: Claire Roger, CHU Nimes

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier:
NCT06043505
Other Study ID Numbers:
  • 2023-A00111-44
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Nīmes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023